{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T03:37:07Z","timestamp":1784432227459,"version":"3.55.0"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,4,1]]},"DOI":"10.2169\/internalmedicine.0072-22","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T22:10:13Z","timestamp":1661811013000},"page":"1055-1058","source":"Crossref","is-referenced-by-count":10,"title":["Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cancer"],"prefix":"10.2169","volume":"62","author":[{"given":"Yuki","family":"Takigawa","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Omote","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Mitsumune","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiriko","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Shibayama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sanders DB. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci 998: 500-508, 2003.","DOI":"10.1196\/annals.1254.065"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Marini A, Bernardini A, Gigli GL, et al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96: 754-766, 2021.","DOI":"10.1212\/WNL.0000000000011795"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nakatani Y, Tanaka N, Enami T, Minami S, Okazaki T, Komuta K. Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep Neurol 10: 346-352, 2018.","DOI":"10.1159\/000494078"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Agrawal K, Agrawal N. Lambert-Eaton myasthenic syndrome secondary to nivolumab and ipilimumab in a patient with small-cell lung cancer. Case Rep Neurol Med 2019: 5353202, 2019.","DOI":"10.1155\/2019\/5353202"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gill AJ, Gandhy S, Lancaster E. Nivolumab-associated Lambert-Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor. Muscle Nerve 63: E18-E21, 2021.","DOI":"10.1002\/mus.27141"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Anderson CJ, Guidon AC, Khan FB, et al. Case report of Lambert Eaton myasthenic syndrome in a patient with small cell lung cancer on immune checkpoint inhibitor therapy. OBM Neurobiol 5: 9, 2021.","DOI":"10.21926\/obm.neurobiol.2101086"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kunii E, Owaki S, Yamada K, et al. Lambert-Eaton myasthenic syndrome caused by atezolizumab in a patient with small-cell lung cancer. Intern Med 61: 1739-1742, 2022.","DOI":"10.2169\/internalmedicine.8387-21"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sakaguchi T, Kokubo Y, Furuhashi K, et al. An extensive-stage small-cell lung cancer case with preexisting Lambert-Eaton myasthenic syndrome successfully treated with an immune checkpoint inhibitor. Clin Lung Cancer 23: e273-e275, 2022.","DOI":"10.1016\/j.cllc.2021.09.001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Dohrn MF, Sch\u00f6ne U, K\u00fcppers C, et al. Immunoglobulins to mitigate paraneoplastic Lambert Eaton myasthenic syndrome under checkpoint inhibition in Merkel cell carcinoma. Neurol Res Pract 2: 52, 2020.","DOI":"10.1186\/s42466-020-00099-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tchouhadjian C, Barlesi F, Doddoli C, et al. Difficulties associated with Lambert-Eaton syndrome. Rev Mal Respir 21: 1167-1170, 2004.","DOI":"10.1016\/S0761-8425(04)71594-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Katada E, Nakamura T, Watanabe H, Matsukawa N, Ojika K, Sobue G. Lambert-Eaton myasthenic syndrome associated with pulmonary squamous cell carcinoma and circulating anti-PQ-type voltage-gated calcium channel antibody. Clin Neurol 50: 17-19, 2010 (in Japanese).","DOI":"10.5692\/clinicalneurol.50.17"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Dai Y, Li P, Yan S, Xia X, Li Z, Xia M. Lung squamous carcinoma with two paraneoplastic syndromes: dermatomyositis and Lambert-Eaton myasthenic syndrome. Clin Respir J 10: 495-499, 2016.","DOI":"10.1111\/crj.12229"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Martin-Moutot N, De Haro L, Seagar M. Distinct evolution of calcium channel antibody types in Lambert-Eaton myasthenic syndrome. J Neuroimmunol 197: 47-53, 2008.","DOI":"10.1016\/j.jneuroim.2008.04.001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Newsom-Davis J. A treatment algorithm for Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 841: 817-822, 1998.","DOI":"10.1111\/j.1749-6632.1998.tb11023.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Zalewski NL, Lennon VA, Lachance DH, Klein CJ, Pittock SJ, Mckeon A. P\/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments. Muscle Nerve 54: 220-227, 2016.","DOI":"10.1002\/mus.25027"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/7\/62_0072-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T03:45:55Z","timestamp":1680320755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/7\/62_0072-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0072-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,1]]},"article-number":"0072-22"}}